Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: A preliminary report

Human Psychopharmacology

Volumn 29, Issue 1, 2014, Pages 94-99

  Bergamaschi, Mateus M ^a,b   Queiroz, Regina H C ^a,b   Chagas, Marcos H N ^a,b   Linares, Ila M P ^a,b   Arrais, Kátia C ^a,b   De Oliveira, Danielle C G ^a,b   Queiroz, Maria E ^a   Nardi, Antonio E ^b,c   Huestis, Marilyn A ^d   Hallak, Jaime E C ^a,b   Zuardi, Antonio W ^a,b   Moreira, Fabrício A ^b,e   Crippa, José A S ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CNPq   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

anxiety; CB1 receptor; public speaking test; rimonabant; SR141716

Indexed keywords

PLACEBO; RIMONABANT;

ADULT; ANXIETY; ARTERIAL PRESSURE; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHYSIOLOGIC MONITORING; PRIORITY JOURNAL; PUBLIC SPEAKING; RANDOMIZED CONTROLLED TRIAL; SEDATION; SELF REPORT; SIMULATION; SINGLE DRUG DOSE; TASK PERFORMANCE; VISUAL ANALOG SCALE; VISUAL ANALOGUE MOOD SCALE; YOUNG ADULT;

ANXIETY; CB1 RECEPTOR; PUBLIC SPEAKING TEST; RIMONABANT; SR141716;

ADULT; ANXIETY; BLOOD PRESSURE; CANNABINOID RECEPTOR ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SPEECH; YOUNG ADULT;

EID: 84892564322     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2374     Document Type: Article

References (40)

1. Beck AT, Epstein N, Brown G, Steer RA,. 1988. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56: 893-897.
2. Bergamaschi MM, Queiroz RH, Chagas MH, et al,. 2011. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36: 1219-1226.
3. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A,. 2007. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706-1713.
4. Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH,. 2000. Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. Br J Psychiatry 176: 379-386.
5. Cunha JA,. 2001. Manual da versão em português das escalas Beck, São Paulo, Casa do Psicõlogo.
6. Del-Ben CM, Vilela JaA, Crippa JaS, Hallak JEC, Labate CM, Zuardi AW,.2001.Confiabilidade da Entrevista Clínica Estruturada para o DSM-IV-Versão Clínica traduzida para o português. Rev Bras Psiquiatr 23:156-159.
7. Engeli S,. 2012. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 209: 357-381.
8. First MB, Spitzer RL, Gibbon M, Williams JBW, 1997. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV). DC, American Psychiatric Press: Washington.
9. Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Huestis MA,. 2006. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J 151: 754 e1-754 e5.
10. Guimaraes FS, Zuardi AW, Graeff FG,. 1987. Effect of chlorimipramine and maprotiline on experimental anxiety in humans. J Psychopharmacol 1: 184-192.
11. Hall W, Degenhardt L,. 2009. Adverse health effects of non-medical cannabis use. The Lancet 374: 1383-1391.
12. Hall W, Solowij N,. 1998. Adverse effects of cannabis. Lancet 352: 1611-1616.
13. Hallak JE, Crippa JA, Quevedo J, et al,. 2010. National Science and Technology Institute for Translational Medicine (INCT-TM): advancing the field of translational medicine and mental health. Revista Brasileira De Psiquiatria 32: 83-90.
14. Haller J, Varga B, Ledent C, Barna I, Freund TF,. 2004. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 19: 1906-1912.
15. Haller J, Barna I, Barsvari B, et al,. 2009. Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 204: 607-616.
16. Hodgson R, Alwyn T, John B, Thom B, Smith A,. 2002. The FAST alcohol screening test. Alcohol Alcohol 37: 61-66.
17. Horder J, Cowen PJ, Di Simplicio M, Browning M, Harmer CJ,. 2009. Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology (Berl) 205: 85-91.
18. Howlett AC, Barth F, Bonner TI, et al,. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
19. Huestis MA, Gorelick DA, Heishman SJ, et al,. 2001. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58: 322-330.
20. Huestis MA, Boyd SJ, Heishman SJ, et al,. 2007. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 194: 505-515.
21. Jacob W, Marsch R, Marsicano G, Lutz B, Wotjak CT,. 2012. Cannabinoid CB1 receptor deficiency increases contextual fear memory under highly aversive conditions and long-term potentiation in vivo. Neurobiol Learn Mem 98: 47-55.
22. Kathuria S, Gaetani S, Fegley D, et al,. 2003. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
23. Kirilly E, Gonda X, Bagdy G,. 2012. CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol (Oxf) 205: 41-60.
24. de Lima Osorio F, Vilela Mendes A, Crippa JA, Loureiro SR., 2009. Study of the discriminative validity of the PHQ-9 and PHQ-2 in a sample of Brazilian women in the context of primary health care. Perspect Psychiatr Care 45: 216-227.
25. Lowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K,. 2004. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care 42: 1194-1201.
26. Mackie K,. 2005. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168: 299-325.
27. Mcintyre RS, Alsuwaidan M, Goldstein BI, et al,. 2012. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry 24: 69-81.
28. McNair DM, Frankenthaler LM, Czerlinsky T, White TW, Sasson S, Fisher S,. 1982. Simulated public speaking as a model of clinical anxiety. Psychopharmacology (Berl) 77: 7-10.
29. Meneses-Gaya C, Crippa JA, Zuardi AW, et al,. 2010. The fast alcohol screening test (FAST) is as good as the AUDIT to screen alcohol use disorders. Subst Use Misuse 45: 1542-1557.
30. Mitchell PB, Morris MJ,. 2007. Depression and anxiety with rimonabant. Lancet 370: 1671-1672.
31. Moreira FA, Crippa JA,. 2009. The psychiatric side-effects of rimonabant. Revista Brasileira De Psiquiatria 31: 145-153.
32. Moreira FA, Wotjak CT,. 2010. Cannabinoids and anxiety. Curr Top Behav Neurosci 2: 429-450.
33. Moreira FA, Kaiser N, Monory K, Lutz B,. 2008. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54: 141-150.
34. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH,. 2007. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192: 61-70.
35. Norris H,. 1971. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10: 181-191.
36. Patel S, Hillard CJ,. 2006. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318: 304-311.
37. Riebe CJ, Pamplona FA, Kamprath K, Wotjak CT,. 2012. Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience 204: 159-185.
38. Viveros MP, Marco EM, File SE,. 2005. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81: 331-342.
39. Zuardi AW, Karniol IG,. 1981. Transcultural evaluation of a self-evaluation scale of subjective states. J Bras Psiquiatr 131: 403-406.
40. Zuardi AW, Crippa JA, Hallak JE,. 2010. Cannabis sativa: the plant that can induce unwanted effects and also treat them. Rev Bras Psiquiatr 32: S1-S2.